Prospective Evaluation of the LithoVue Elite Ureteroscope
NCT ID: NCT04900688
Last Updated: 2024-06-07
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
NA
Total Enrollment
150 participants
Study Classification
INTERVENTIONAL
Study Start Date
2023-01-16
Study Completion Date
2025-09-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Flexible ureteroscopy has become the main surgical treatment for kidney stone disease. The procedure uses many types of ureteroscopes (disposable and non-disposable). Currently we are using the LithoVue Single-Use Digital Flexible Ureteroscope. The Health Canada approved LithoVue Elite disposable flexible ureteroscope will now offer novel pressure sensory capacity. In order to evaluate the new ureteroscopy we will be conducting a prospective multi-institution study in order to determine the main features, capacity and abilities of the new scope. We will evaluate the impact of intra renal pressure on pain, quality of life and possible infectious complications.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
LithoVue Single Use Disposable Ureteroscope
NCT03419091
Kidney Stone
UNKNOWN
NA
Enhanced Lithotripsy System (ELS) in the Treatment of Urinary Stone Disease
NCT03339388
Urinary Stone
TERMINATED
NA
Evaluation of the LithoVue Elite Ureteroscope With Intra-Renal Pressure Monitoring Technology: Examination of Surgeon Behavior and Post-operative Outcomes
NCT06576661
Kidney Stone
Nephrolithiasis
RECRUITING
NA
ILY Robotic System vs Manual Flexible Ureteroscopy for Kidney Stone Treatment
NCT06996587
Kidney Stones
Urolithiasis
RECRUITING
NA
Evaluation of Enhanced Lithotripsy System (ELS) in the Treatment of Urinary Stones, A Pivotal Trial
NCT06942949
Kidney Calculi; Ureteral Calculi
RECRUITING
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is a single arm multicenter study looking at real world results of ureteroscopy with the new digital flexible ureteroscope LVE. The study will involve 6 participating institutions. Each site will be in charge of recruiting 25 participants for a total of 150 participants.
Hypothesis:
1. The single-use flexible ureteroscope (Lithovue Elite) will provide equivalent overall performance to a standard-of-care reusable or disposable ureteroscope as determined by:
* Stone-free rate following ureteroscopy at 4-8 weeks post-procedure
* Equivalent adjunctive procedures in the postoperative period
* Intraoperative assessment parameters will show no difference between the Lithovue Elite scope and other standard-of-care ureteroscopes
2. Elevated intrarenal pressures during ureteroscopes will result in:
* Higher post-operative pain intensity as documented in the Brief Pain Inventory-BPI
* Lower quality of life as reflected via Wisconsin Stone Quality of Life Questionnaire scores
* Higher rates of infections complications
* Changes in neutrophil gelatinase-associated lipocalin (NGAL) from baseline
Procedures:
Patients who will undergo ureteroscopy and laser lithotripsy will be screened for eligibility. The stone burden needs to be less than 20 mm in total to be eligible. Patients with a nephrostomy tube are ineligible as the nephrostomy tube may affect the intraoperative renal pressure. Patients undergoing bilateral ureteroscopy are eligible to participate.
Eligible patients will be approached to participate in the study, their consent will be obtained and each participant will be assigned an identification number to code his/her data. Patients will undergo standard-of-care ureteroscopy under anesthesia specific to the investigator's site.
Preoperatively, patients who have an indication to undergo ureteroscopy will have imaging and fill out a WISQOL and BPI questionnaire at baseline. Baseline urine analysis is required and culture if indicated as per standard of care. Bloodwork is performed as per institutional standard of care. In addition, a urine sample will be obtained and stored (-20C) for NGAL measurement. The standard-of-care at each site will be used for antibiotics and whether the procedure is performed as an outpatient procedure or if the patient is admitted to the hospital post-operatively The day of surgery, the ureteroscopy will be performed using the new digital flexible ureteroscope LithoVue Elite (LVE). It will be carried out as per the surgeon's preference as to the use of a safety guidewire, use of ureteral access sheath (UAS), basketing stones or dusting, type of laser used, and laser settings. The irrigation used will be recorded and used as per the surgeon's preference. The pressure readings from LVE will be recorded. A decision on whether to leave a stent and its indwelling time is left up to the surgeon. Stone (s) will be sent for laboratory analysis.
In the recovery room after the procedure, the patient will have their Quick Sequential Organ Failure Assessment Score (QSOFA) score measured (systolic blood pressure, mentation status (GCS), and respiratory rate) as well as complete the BPI. In addition, a urine sample will be obtained and stored (-20C) for NGAL measurement as well as any other laboratory tests requested by the investigator. Postoperative antibiotics, analgesics (e.g. Tylenol, NSAID, +/- opioid) and discharge medication (e.g. NSAIDS, Opioids, Anticholinergics, Alpha blockers) prescriptions are left to the discretion of surgeon and will be recorded.
Within 1-2 weeks, participants who have a stent will come to the hospital for stent removal. Stents can be removed in any fashion (tether string or cystoscopy), this decision is left up to the surgeon. Participants who have no stent in place might have an in-person or remote follow-up depending on COVID 19 restrictions. Participants will have to also complete the BPI and WISQOL.
Within 4-8 weeks postoperatively, patients will undergo standard of care imaging with either a combination of KUB x-ray and renal-bladder ultrasound or a low-dose CT scan. The choice of modality will be left to the surgeon discretion depending on institutional standards, surgeon preference and stone type. The stone free rate will be recorded based on imaging results. Participants will complete the BPI and WISQOL. The patient will have completed the study.
Study visits and measurements:
Preoperative visit (V0) : During this visit we will record:
1. Demographics data: sex, date of birth (month and year), date of surgery, age, height, weight, BMI, comorbidities, Charlson Comorbidity Index.
2. Preoperative data: Stent preop, blood work, urine analysis, urine culture, treatment of UTI, baseline NGAL measurement, imaging modality, medication.
3. Stone- related data based on imaging results: Number of stones, Stone location, size (length, width, height), volume, DICOM Volume and density (HU)
4. Patient reported outcomes: participants will complete the WisQOL, and BPI (baseline).
Day of surgery visit (V1) : During this visit we will perform ureteroscopy with laser lithotripsy per usual and collect the following data:
1. Intraoperative data: ASA score, date and duration of surgery, type of anesthesia, type of procedure, use of Ureteral Access Sheath (UAS), Safety Guide Wire (SGW), Laser and their related information (type, size, settings), surgical technique (basketing or dusting), irrigation related information, intraoperative pressure measurement, use of stent and strings, perioperative antibiotics, intraoperative complications, ability to navigate all areas of the kidney and complete the entire case using one-single use ureteroscope.
2. Recovery room data: QSOFA, NGAL measurement, postoperative analgesics, discharge medication and postoperative antibiotics.
3. Patient reported outcomes: At discharge from the recovery room participants will complete the BPI.
Postoperative visit (V2): Within 1-2 weeks we will remove the stent and record;
1. Postoperative data: Date of stent removal and stent indwelling time when applicable
2. Patient reported outcomes: Participants will complete the WisQOL and BPI
Postoperative visit (V3): Within 4-8 weeks postoperatively, patients will undergo standard of care imaging. During this visit we will record:
1. Postoperative information: Postoperative imaging modality and Stone-free Rate (SFR), type of stone (s) based on stone's laboratory analysis and 30 days-postoperative complications.
2. Patient reported outcomes: Participants will complete the WisQOL and BPI.
Additional variables collected allowing ancillary studies. Medical charts of participants and surgical protocol will be reviewed to collect the information needed for this study.
Data collection, management, storage and conservation:
Data collection and management:
A urine sample will be drawn for NGAL measurement at V0 and V1. The sample will be stored in a freezer at -20C at each participating center. Analysis of urine samples will done at the University of British Columbia's laboratory in Vancouver, shipment of samples for analysis will be done once, at the end of the study. Samples will be destroyed after analysis.
Redcap database will be used for data collection. Each participating center will be provided an access to CHUM's REDCap to enter all data requested during the study (demographic data as well as patient reported outcomes, clinical data, imaging and laboratory results). Patient reported outcomes-related questionnaires can be sent via REDCap powered emails to be completed online or given to participants in paper form depending on the site's preference.
Data storage and conservation:
Nominal data as well as the file that links identification information with the code assigned to each participant will be stored and kept at each participating institution as required by each institution's Research Ethics Board.
No identification data will be stored on REDCap, except the e-mail address of participants for the sites that will use REDCap powered emails to send the questionnaires to participants. Data collected and stored on REDCap will be coded and the e-mail address of participants will be removed at the time of data extraction for analysis.
Only the members of the Central Coordinating Research Team at the CHUM who are involved in the study, the local coordinators at participating sites and the REDCap data manager at the CHUM will have access to data stored on REDCap. The data collected using REDCap will be hosted on secure CHUM servers.
There is no blinding during this study and it is not an interventional trial so emergency access to the database is not necessary for patient care. It is an observational trial and measuring patient reported outcomes. At the end of the study, data collected via REDCap will be downloaded for analysis, stored on the network drive of Dr. Naeem Bhojani at the CHUM and kept for 10 years.
Ethical considerations:
The procedures of this study fall within standard-of-care, and as such all prospective patients to be enrolled in this study will receive the same care whether they are included in the study or not. These patients may withdraw from the study at any time without any negative consequences to the medical care, education, or other services to which they are entitled or are presently receiving.
Intrarenal pressure measurements during the study ureteroscopy procedure is not part of the standard of care and is done for research purposes only. There is no additional risk to the patient when monitoring this pressure and patients will be informed of this during the informed consent process.
NGAL measurement is a measurement that is not part of standard of care, at the preoperative visit urine analysis are done as part of usual care, the medical staff will ask patients for an additional urine sample to be stored (-20C) for NGAL measurement. Right after their ureteroscopy (V1) while in the recovery room, no urine sample is drawn as part of standard care, we will ask participants to provide a urine sample exclusively for NGAL measurement but participants will be informed of this. No more NGAL measurements are required as part of study procedures.
Approached participants will be asked to provide their consent. Paper or electronic consent might be used depending on participating site preferences and Research Ethics Board requirements. Electronic consent might be obtained via REDCap or other means/platforms as authorized by each participating site Research Ethics Boards.
Data collected during this study will be kept for 10 years. The results will be presented at conferences and published in journals; however, precautions will be taken to ensure that at the time of dissemination, the study participants will not be identifiable.
Funding:
This is an investigator-initiated trial and there is no funding for this study.
Conflict of interest:
Although this is an investigator-initiated study, it should be noted that the principal investigator (Dr Naeem Bhojani) and the Co-Principal investigator (Dr. Ben Chew) are consultants for Boston Scientific, the manufacturer of the LithoVue Elite disposable flexible ureteroscope under evaluation.
Hypothesis:
1. The single-use flexible ureteroscope (Lithovue Elite) will provide equivalent overall performance to a standard-of-care reusable or disposable ureteroscope as determined by:
* Stone-free rate following ureteroscopy at 4-8 weeks post-procedure
* Equivalent adjunctive procedures in the postoperative period
* Intraoperative assessment parameters will show no difference between the Lithovue Elite scope and other standard-of-care ureteroscopes
2. Elevated intrarenal pressures during ureteroscopes will result in:
* Higher post-operative pain intensity as documented in the Brief Pain Inventory-BPI
* Lower quality of life as reflected via Wisconsin Stone Quality of Life Questionnaire scores
* Higher rates of infections complications
* Changes in neutrophil gelatinase-associated lipocalin (NGAL) from baseline
Procedures:
Patients who will undergo ureteroscopy and laser lithotripsy will be screened for eligibility. The stone burden needs to be less than 20 mm in total to be eligible. Patients with a nephrostomy tube are ineligible as the nephrostomy tube may affect the intraoperative renal pressure. Patients undergoing bilateral ureteroscopy are eligible to participate.
Eligible patients will be approached to participate in the study, their consent will be obtained and each participant will be assigned an identification number to code his/her data. Patients will undergo standard-of-care ureteroscopy under anesthesia specific to the investigator's site.
Preoperatively, patients who have an indication to undergo ureteroscopy will have imaging and fill out a WISQOL and BPI questionnaire at baseline. Baseline urine analysis is required and culture if indicated as per standard of care. Bloodwork is performed as per institutional standard of care. In addition, a urine sample will be obtained and stored (-20C) for NGAL measurement. The standard-of-care at each site will be used for antibiotics and whether the procedure is performed as an outpatient procedure or if the patient is admitted to the hospital post-operatively The day of surgery, the ureteroscopy will be performed using the new digital flexible ureteroscope LithoVue Elite (LVE). It will be carried out as per the surgeon's preference as to the use of a safety guidewire, use of ureteral access sheath (UAS), basketing stones or dusting, type of laser used, and laser settings. The irrigation used will be recorded and used as per the surgeon's preference. The pressure readings from LVE will be recorded. A decision on whether to leave a stent and its indwelling time is left up to the surgeon. Stone (s) will be sent for laboratory analysis.
In the recovery room after the procedure, the patient will have their Quick Sequential Organ Failure Assessment Score (QSOFA) score measured (systolic blood pressure, mentation status (GCS), and respiratory rate) as well as complete the BPI. In addition, a urine sample will be obtained and stored (-20C) for NGAL measurement as well as any other laboratory tests requested by the investigator. Postoperative antibiotics, analgesics (e.g. Tylenol, NSAID, +/- opioid) and discharge medication (e.g. NSAIDS, Opioids, Anticholinergics, Alpha blockers) prescriptions are left to the discretion of surgeon and will be recorded.
Within 1-2 weeks, participants who have a stent will come to the hospital for stent removal. Stents can be removed in any fashion (tether string or cystoscopy), this decision is left up to the surgeon. Participants who have no stent in place might have an in-person or remote follow-up depending on COVID 19 restrictions. Participants will have to also complete the BPI and WISQOL.
Within 4-8 weeks postoperatively, patients will undergo standard of care imaging with either a combination of KUB x-ray and renal-bladder ultrasound or a low-dose CT scan. The choice of modality will be left to the surgeon discretion depending on institutional standards, surgeon preference and stone type. The stone free rate will be recorded based on imaging results. Participants will complete the BPI and WISQOL. The patient will have completed the study.
Study visits and measurements:
Preoperative visit (V0) : During this visit we will record:
1. Demographics data: sex, date of birth (month and year), date of surgery, age, height, weight, BMI, comorbidities, Charlson Comorbidity Index.
2. Preoperative data: Stent preop, blood work, urine analysis, urine culture, treatment of UTI, baseline NGAL measurement, imaging modality, medication.
3. Stone- related data based on imaging results: Number of stones, Stone location, size (length, width, height), volume, DICOM Volume and density (HU)
4. Patient reported outcomes: participants will complete the WisQOL, and BPI (baseline).
Day of surgery visit (V1) : During this visit we will perform ureteroscopy with laser lithotripsy per usual and collect the following data:
1. Intraoperative data: ASA score, date and duration of surgery, type of anesthesia, type of procedure, use of Ureteral Access Sheath (UAS), Safety Guide Wire (SGW), Laser and their related information (type, size, settings), surgical technique (basketing or dusting), irrigation related information, intraoperative pressure measurement, use of stent and strings, perioperative antibiotics, intraoperative complications, ability to navigate all areas of the kidney and complete the entire case using one-single use ureteroscope.
2. Recovery room data: QSOFA, NGAL measurement, postoperative analgesics, discharge medication and postoperative antibiotics.
3. Patient reported outcomes: At discharge from the recovery room participants will complete the BPI.
Postoperative visit (V2): Within 1-2 weeks we will remove the stent and record;
1. Postoperative data: Date of stent removal and stent indwelling time when applicable
2. Patient reported outcomes: Participants will complete the WisQOL and BPI
Postoperative visit (V3): Within 4-8 weeks postoperatively, patients will undergo standard of care imaging. During this visit we will record:
1. Postoperative information: Postoperative imaging modality and Stone-free Rate (SFR), type of stone (s) based on stone's laboratory analysis and 30 days-postoperative complications.
2. Patient reported outcomes: Participants will complete the WisQOL and BPI.
Additional variables collected allowing ancillary studies. Medical charts of participants and surgical protocol will be reviewed to collect the information needed for this study.
Data collection, management, storage and conservation:
Data collection and management:
A urine sample will be drawn for NGAL measurement at V0 and V1. The sample will be stored in a freezer at -20C at each participating center. Analysis of urine samples will done at the University of British Columbia's laboratory in Vancouver, shipment of samples for analysis will be done once, at the end of the study. Samples will be destroyed after analysis.
Redcap database will be used for data collection. Each participating center will be provided an access to CHUM's REDCap to enter all data requested during the study (demographic data as well as patient reported outcomes, clinical data, imaging and laboratory results). Patient reported outcomes-related questionnaires can be sent via REDCap powered emails to be completed online or given to participants in paper form depending on the site's preference.
Data storage and conservation:
Nominal data as well as the file that links identification information with the code assigned to each participant will be stored and kept at each participating institution as required by each institution's Research Ethics Board.
No identification data will be stored on REDCap, except the e-mail address of participants for the sites that will use REDCap powered emails to send the questionnaires to participants. Data collected and stored on REDCap will be coded and the e-mail address of participants will be removed at the time of data extraction for analysis.
Only the members of the Central Coordinating Research Team at the CHUM who are involved in the study, the local coordinators at participating sites and the REDCap data manager at the CHUM will have access to data stored on REDCap. The data collected using REDCap will be hosted on secure CHUM servers.
There is no blinding during this study and it is not an interventional trial so emergency access to the database is not necessary for patient care. It is an observational trial and measuring patient reported outcomes. At the end of the study, data collected via REDCap will be downloaded for analysis, stored on the network drive of Dr. Naeem Bhojani at the CHUM and kept for 10 years.
Ethical considerations:
The procedures of this study fall within standard-of-care, and as such all prospective patients to be enrolled in this study will receive the same care whether they are included in the study or not. These patients may withdraw from the study at any time without any negative consequences to the medical care, education, or other services to which they are entitled or are presently receiving.
Intrarenal pressure measurements during the study ureteroscopy procedure is not part of the standard of care and is done for research purposes only. There is no additional risk to the patient when monitoring this pressure and patients will be informed of this during the informed consent process.
NGAL measurement is a measurement that is not part of standard of care, at the preoperative visit urine analysis are done as part of usual care, the medical staff will ask patients for an additional urine sample to be stored (-20C) for NGAL measurement. Right after their ureteroscopy (V1) while in the recovery room, no urine sample is drawn as part of standard care, we will ask participants to provide a urine sample exclusively for NGAL measurement but participants will be informed of this. No more NGAL measurements are required as part of study procedures.
Approached participants will be asked to provide their consent. Paper or electronic consent might be used depending on participating site preferences and Research Ethics Board requirements. Electronic consent might be obtained via REDCap or other means/platforms as authorized by each participating site Research Ethics Boards.
Data collected during this study will be kept for 10 years. The results will be presented at conferences and published in journals; however, precautions will be taken to ensure that at the time of dissemination, the study participants will not be identifiable.
Funding:
This is an investigator-initiated trial and there is no funding for this study.
Conflict of interest:
Although this is an investigator-initiated study, it should be noted that the principal investigator (Dr Naeem Bhojani) and the Co-Principal investigator (Dr. Ben Chew) are consultants for Boston Scientific, the manufacturer of the LithoVue Elite disposable flexible ureteroscope under evaluation.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Kidney Stone
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Single arm multicenter study looking at real world results of ureteroscopy with the new digital flexible ureteroscope.
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ureteroscopy (URS) with the LithoVue Elite disposable flexible ureteroscope
Ureteroscopy will be done using the LithoVue Elite disposable flexible ureteroscope instead of the satandard ureteroscope
Group Type
OTHER
LithoVue Elite
Intervention Type
DEVICE
LithoVue Elite is a disposable flexible ureteroscope that offer novel pressure sensory capacity
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
LithoVue Elite
LithoVue Elite is a disposable flexible ureteroscope that offer novel pressure sensory capacity
Intervention Type
DEVICE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient scheduled for ureteroscopy and laser lithotripsy
* Non-obstructing renal stone 2 cm total stone diameter (if multiple stones, then sum of maximum diameters) or less undergoing flexible ureteroscopy
* age \> 18 years
* Non-obstructing renal stone 2 cm total stone diameter (if multiple stones, then sum of maximum diameters) or less undergoing flexible ureteroscopy
* age \> 18 years
Exclusion Criteria
* age \< 18 years
* pregnancy status =positive
* indwelling nephrostomy tube
* severe hydronephrosis that in the opinion of the investigator, will make it challenging to make the patient stone free
* renal anomalies
* pregnancy status =positive
* indwelling nephrostomy tube
* severe hydronephrosis that in the opinion of the investigator, will make it challenging to make the patient stone free
* renal anomalies
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of British Columbia
OTHER
Sponsor Role
collaborator
Western University, Canada
OTHER
Sponsor Role
collaborator
Université de Montréal
OTHER
Sponsor Role
collaborator
University of Saskatchewan
OTHER
Sponsor Role
collaborator
Laval University
OTHER
Sponsor Role
collaborator
Centre hospitalier de l'Université de Montréal (CHUM)
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Naeem Dr Bhojani, MD
Role: PRINCIPAL_INVESTIGATOR
Centre hospitalier de l'Université de Montréal (CHUM)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Vancouver General Hospital
Vancouver, British Columbia, Canada
Site Status
NOT_YET_RECRUITING
Western University
London, Ontario, Canada
Site Status
NOT_YET_RECRUITING
Centre Hospitalier de l'Université de Montréal (CHUM)
Montreal, Quebec, Canada
Site Status
RECRUITING
Hôpital Maisonneuve-Rosemont (HMR)
Montreal East, Quebec, Canada
Site Status
NOT_YET_RECRUITING
CHU de Québec-Université Laval
Québec, Quebec, Canada
Site Status
NOT_YET_RECRUITING
University of Saskatchewan
Saskatoon, Saskatchewan, Canada
Site Status
NOT_YET_RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Canada
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Benli E, Ayyildiz SN, Cirrik S, Noyan T, Ayyildiz A, Cirakoglu A. Early term effect of ureterorenoscopy (URS) on the Kidney: research measuring NGAL, KIM-1, FABP and CYS C levels in urine. Int Braz J Urol. 2017 Sep-Oct;43(5):887-895. doi: 10.1590/S1677-5538.IBJU.2016.0638.
Reference Type
BACKGROUND
Fahmy N, Sener A, Sabbisetti V, Nott L, Lang RM, Welk BK, Mendez-Probst CE, MacPhee RA, VanEerdewijk S, Cadieux PA, Bonventre JV, Razvi H. Urinary expression of novel tissue markers of kidney injury after ureteroscopy, shockwave lithotripsy, and in normal healthy controls. J Endourol. 2013 Dec;27(12):1455-62. doi: 10.1089/end.2013.0188. Epub 2013 Nov 1.
Reference Type
BACKGROUND
Penniston KL, Antonelli JA, Viprakasit DP, Averch TD, Sivalingam S, Sur RL, Pais VM Jr, Chew BH, Bird VG, Nakada SY. Validation and Reliability of the Wisconsin Stone Quality of Life Questionnaire. J Urol. 2017 May;197(5):1280-1288. doi: 10.1016/j.juro.2016.11.097. Epub 2016 Nov 23.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MP-02-2022-9937
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
To Evaluate the Safety and Efficacy of LithoVue Ureteroscope System in Chinese Patients With Urinary Disease
NCT03676972
COMPLETED
NA
Efficacy of Semi-rigid Ureteroscopic Laser Lithotripsy in the Treatment of Proximal Ureteral Stones: a Randomized Controlled Trial
NCT06489366
NOT_YET_RECRUITING
NA
LithoVue Elite Registry
NCT05201456
WITHDRAWN
Efficacy and Safety of Ureteroscopic Lithotripsy (Including Flexible Ureteroscopy) Without Indwelling Urinary Catheter
NCT06458101
COMPLETED
NA
Use of a Ureteral Access Sheath During Ureteroscopy and Its Effect on Stone Free Rate
NCT00199524
TERMINATED
PHASE4
Evaluation of the Performance of a Robotic Flexible Ureteroscopy (ILY) in Laser Treatment of Nephrolithiasis
NCT03638336
WITHDRAWN
NA
Massage Percussion for Passage of Urolithiasis Fragments After Ureteroscopy.
NCT05872230
TERMINATED
NA
Evaluation of Novel Disposable Flexible Ureteroscope for the Treatment of Renal Calculi
NCT05646069
COMPLETED
NA
Stent Omission After Ureteroscopy and Lithotripsy in the Michigan Urological Surgery Improvement Collaborative
NCT05866081
RECRUITING
NA
A Comparison of Ureteroscopic Treatment of Nephrolithiasis With and Without Moses Technology
NCT04505956
COMPLETED
NA
Acoustic Enhancer Research on Laser Lithotripsy (AEROLITH)
NCT04563039
COMPLETED
NA
Evaluation of Ureteral Stents in the Management of Stone Disease
NCT02211313
TERMINATED
NA
The StoneBreakerTM Trial
NCT00677196
COMPLETED
PHASE3
Tip-flexible Semi-rigid Ureterorenoscope Versus Flexible Ureteroscopy in Renal Calculi
NCT02426931
UNKNOWN
NA
Extracorporeal Shock Wave Lithotriptor Indicated for Fragmenting Urinary Stones in the Kidney
NCT00959153
UNKNOWN
PHASE3
Flexible urétéroscopy Versus Extracorporeal Shockwave Lithotripsy in Renal Calculi
NCT01604304
COMPLETED
NA
Ultrasound Imaging of Kidney Stones and Lithotripsy
NCT02214836
ACTIVE_NOT_RECRUITING
NA
Comparing Efficiency and Stone-Free Rates Mini PCNL vs Flex URS
NCT07072598
NOT_YET_RECRUITING
NA
Impact Ureteral Sheath Design During Ureteroscopy
NCT03349099
COMPLETED
NA
Feasibility Study of the Uriprene Stent Following Uncomplicated Ureteroscopy
NCT02032316
COMPLETED
PHASE1
Ureteral Stent Placement After Ureteroscopy for Renal Stones: A Randomized Controlled Trial
NCT03855787
COMPLETED
NA
Single-use Digital Flexible Ureteroscope vs Nondisposable Fiber Optic vs Digital Ureteroscope
NCT03220516
UNKNOWN
NA
The Performance of the SOLTIVE Laser System for Laser Lithotripsy in Kidney or Ureteral Stones
NCT04556201
COMPLETED
NA